The chronic obstructive pulmonary disease (COPD) market is experiencing increased competition as newer combination therapies vie with long-marketed stalwarts Spiriva, Advair, and Symbicort. Current…
MARKET OUTLOOK The chronic obstructive pulmonary disease (COPD) market is experiencing increased competition as newer combination therapies vie with long-marketed stalwarts Spiriva, Advair, and…
Biomarker-driven prescribing is entrenched in indications such as non-small-cell lung cancer (NSCLC) and malignant melanoma and is playing an increasingly important role in indications such as…
Market Outlook: Biomarker-driven prescribing is entrenched in indications such as non-small-cell lung cancer (NSCLC) and malignant melanoma and is playing an increasingly important role in…
Immune checkpoint inhibitors are now at the center of the clinical treatment of metastatic non-small-cell lung cancer (NSCLC). In 2017, the European Commission granted successive approvals to three…
Immune checkpoint inhibitors are now at the center of the clinical treatment of metastatic non-small-cell lung cancer (NSCLC). In 2017, the European Commission granted successive approvals to three…
DRG Epidemiology’s coverage of diabetic neuropathy comprises epidemiological estimates of key patient populations in 45 countries worldwide. We report the prevalence of diabetic neuropathy for…
Introduction: Non-Hodgkin’s lymphoma (NHL) is a heterogeneous group of malignancies that can be broadly classified into indolent and aggressive subtypes. The treatment algorithm for NHL …
MARKET OUTLOOK Psoriasis Current Treatment: Physician Insights probes the current and future use of topical agents, phototherapy, and systemic therapies in the treatment of mild, moderate, and…
MARKET OUTLOOK The well-established antimuscarinic drug class dominates the overactive bladder (OAB) therapy market, and the continued generic erosion of these agents will be the most significant…
A large array of clinically unique disease-modifying therapies (DMTs) is approved for the treatment of multiple sclerosis (MS) in the United States. Competition in this crowded market has…
According to DRG epidemiology, more than 33 million people in the EU5 suffer from migraines and over 10% of migraineurs suffer from chronic migraine (CM). Migraine prophylaxis is a core treatment…
Prior to the launch of Hemlibra, the hemophilia market consisted solely of factor-based products. The use of factor concentrate is highly varied; brand-dependent dosing and infusion frequencies,…
Osteoarthritic (OA) pain is a prevalent subtype of chronic pain, affecting more than 43 million individuals in the EU5. OA pain treatment decisions are driven primarily by rheumatologists,…
Copy/Paste the key inputs from the product brochure, per guidance from Solutions. Osteoarthritic (OA) pain is a prevalent subtype of chronic pain, affecting more than 43 million individuals in the…
